Grover, S A <br/><br/>
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.  [electronic resource] 

 -  Archives of internal medicine  Mar 1999 
 - 593-600 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0003-9926 
<br/><br/><label>Standard No.: </label>10.1001/archinte.159.6.593  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Canada<br/>Cardiovascular Diseases--economics<br/>Cerebrovascular Disorders--economics<br/>Cost-Benefit Analysis<br/>Drug Costs<br/>Female<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--economics<br/>Hypolipidemic Agents--economics<br/>Life Expectancy<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Risk<br/>Scandinavian and Nordic Countries<br/>Sensitivity and Specificity<br/>Simvastatin--economics